Letter to Editor
Year 2019,
Volume: 5 Issue: 4, 719 - 721, 04.07.2019
Abstract
No abstract available.
References
- [1] Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178:1932-9.
- [2] Engel EE, Brassesco MS, Valera ET, Barbosa MHN,Yamashita MEAS, Scrideli CA, et al. Clinico-genetic aspects of a pediatric non-neurofibromatosis type 1 malignant triton tumor with loss of chromosome X. Pediatr Blood Cancer 2012;59:1320-3.
- [3] Kamran SC, Howard SA, Shinagare AB, Krajewski KM. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. EJSO 2013;39:46-52.
- [4] McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012;106:51-6.
- [5] Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 2007;20:135-41.
- [6] Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012;19:878-85.
- [7] Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97:340-9.
- [8] Ferner RE, Gutmann DG. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 2002;62:1573-7.
- [9] Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM.. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 2011;34:417-21.
Year 2019,
Volume: 5 Issue: 4, 719 - 721, 04.07.2019
Abstract
References
- [1] Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178:1932-9.
- [2] Engel EE, Brassesco MS, Valera ET, Barbosa MHN,Yamashita MEAS, Scrideli CA, et al. Clinico-genetic aspects of a pediatric non-neurofibromatosis type 1 malignant triton tumor with loss of chromosome X. Pediatr Blood Cancer 2012;59:1320-3.
- [3] Kamran SC, Howard SA, Shinagare AB, Krajewski KM. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. EJSO 2013;39:46-52.
- [4] McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012;106:51-6.
- [5] Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 2007;20:135-41.
- [6] Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012;19:878-85.
- [7] Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97:340-9.
- [8] Ferner RE, Gutmann DG. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 2002;62:1573-7.
- [9] Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM.. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 2011;34:417-21.
There are 9 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Dermatology, Oncology and Carcinogenesis, Neurology and Neuromuscular Diseases, Rehabilitation |
| Journal Section | Letters to the Editor |
| Authors | |
| Publication Date | July 4, 2019 |
| Submission Date | September 26, 2018 |
| Acceptance Date | February 26, 2019 |
| Published in Issue | Year 2019 Volume: 5 Issue: 4 |
e-ISSN: 2149-3189
The European Research Journal, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2024